Market Characterization of Global Respiratory Therapeutics Market

The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

“The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global respiratory diseases therapeutics market. The report analyzes the markets for respiratory disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. ( ?id=128484&rt=The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html )

Scope

The scope of this report includes:

- Annualized market data for the respiratory diseases therapeutics market from 2000 to 2008, forecast forward to 2015
- Analysis of the leading therapeutic segments including asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension and cystic fibrosis
- Analysis of the respiratory diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the respiratory diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Novartis AG, AstraZeneca and Merck & Co
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global respiratory diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

To know more and to buy a copy of your report feel free to visit : ?id=128484&rt=The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html" ?id=128484&rt=The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html


Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: mailto:info@bharatbook.com" info@bharatbook.com
Website:
Blog:
Follow us on twitter: